您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Argatroban
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Argatroban
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Argatroban图片
CAS NO:74863-84-6
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
10mg电议
50mg电议

产品介绍
Argatroban (MD-805) 是一种直接的、选择性的凝血酶抑制剂。
Cas No.74863-84-6
别名阿加曲班; MD-805; MCI-9038; Argipidine
化学名(2R,4R)-1-((S)-5-((diaminomethylene)amino)-2-((R)-3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonamido)pentanoyl)-4-methylpiperidine-2-carboxylic acid
Canonical SMILESO=C([C@H](CCC/N=C(N)/N)NS(=O)(C1=C2NC[C@H](C)CC2=CC=C1)=O)N3[C@@H](C(O)=O)C[C@H](C)CC3
分子式C23H36N6O5S
分子量508.63
溶解度≥ 25.25mg/mL in DMSO
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Argatroban (MD-805) is a direct, selective thrombin inhibitor.

Argatroban (MD-805) may have a complementary effect for preventing thrombus formation without aggravating bleeding tendency because of its monotarget specificity to thrombin. Administration (0.5 to 2 micrograms/kg/min) of Argatroban (MD-805) is a safe anticoagulant for left heart bypass in repairs of traumatic aortic rupture associated with multiple organ injuries[1]. Argatroban (MD-805), as compared with heparin, appears to enhance reperfusion with TPA in patients with AMI, particularly in those patients with delayed presentation. The incidences of major bleeding and adverse clinical outcome were lower in the patients receiving argatroban[2].

References:
[1]. Kawada, T., et al., Argatroban, an attractive anticoagulant, for left heart bypass with centrifugal pump for repair of traumatic aortic rupture. Jpn J Thorac Cardiovasc Surg, 1999. 47(3): p. 104-9.
[2]. Jang, I.K., et al., A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol, 1999. 33(7): p. 1879-85.